Medtherapy, a cancer gene therapy biotechnology company, has unveiled its strategic vision to make India a global hub for manufacturing gene therapies, with a primary focus on the innovative cancer treatment CAR-T Cell Therapy. The therapy, first approved by the US Food and Drug Administration (FDA) in 2017, has since been hailed as a potential “cure” for certain cancers.

The company said its Phase 1 trial conducted in the United States showed encouraging clinical responses among cancer patients.